Skip to main content
TipRanks
Go Ultimate75% OFF

Endonovo Therapeutics (ENDV) Stock Price & Analysis

24 Followers

ENDV Stock Chart & Stats

$0.00$0.00(100.00%)
At close: 1:32 PM EDT
$0.01$0.012$0.014Sep 26Oct 9Oct 23Nov 6Nov 20Dec 1Dec 19
Day’s Range
$0.01 - $0.01
52-Week Range
N/A
Previous Close
$0.01
Volume
N/A
Average Volume (3M)
92.65K
Market Cap
$180.76K
Enterprise Value
$6.93T
Total Cash (Recent Filing)
$13.68K
Total Debt (Recent Filing)
$7.09M
Price to Earnings (P/E)
―
Beta
280.11
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Innovative Product Offering

Endonovo's focus on non-invasive, bioelectronic therapies positions it well in the growing field of regenerative medicine, offering a unique solution for pain management and recovery.

Revenue Model Diversity

A diverse revenue model including sales, leases, and partnerships enhances revenue stability and potential growth through multiple streams.

Cash Flow Improvement

Improvement in free cash flow indicates better cash management, which is crucial for sustaining operations and funding future growth initiatives.

Bears Say

Financial Instability

Negative equity and high liabilities indicate financial distress, posing risks to long-term viability and limiting strategic options.

Revenue Decline

Inconsistent revenue trends undermine financial stability and growth prospects, challenging the company's ability to sustain operations.

Profitability Challenges

Negative margins highlight operational inefficiencies and cost management issues, impacting the company's ability to achieve profitability.

ENDV FAQ

What is Endonovo Therapeutics’s market cap?
Endonovo Therapeutics’s market cap is $180.76K.
When is Endonovo Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Endonovo Therapeutics’s earnings last quarter?
Endonovo Therapeutics released its earnings results on Nov 18, 2024. The company reported -$0.002 earnings per share for the quarter.
Is Endonovo Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Endonovo Therapeutics pay dividends?
Endonovo Therapeutics does not currently pay dividends.
What is Endonovo Therapeutics’s EPS estimate?
Endonovo Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Endonovo Therapeutics have?
Endonovo Therapeutics has 1,807,556,300 shares outstanding.
What happened to Endonovo Therapeutics’s price movement after its last earnings report?
Endonovo Therapeutics reported an EPS of -$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Endonovo Therapeutics?
Currently, no hedge funds are holding shares in ENDV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology